Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells

Eva Maria Weissinger, Sylvia Borchers, Anna Silvani, Elena Provasi, Marina Radrizzani, Irene Katarina Beckmann, Claudia Benati, Joerg Schmidtke, Wolfgang Kuehnau, Patrick Schweier, Susanne Luther, Ivonne Fernandez-Munoz, Gernot Beutel, Fabio Ciceri, Chiara Bonini, Arnold Ganser, Bernd Hertenstein, Michael Stadler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for hematologic malignancies, but is hampered by severe complications, such as acute or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selcetion of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. Thus, we studied the efficacy, safety and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte transfusion (DLI). The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-Tk and the truncated LNGFR for selection of transduced cells. Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors).Nine patients were included in the first trial (MHH; 2002 until 2007) 2 were included in TK007 (2005-2009) and 6 serve as a control group for outcome after haploidentical transplantation without HSV-TKtransduced DLI. Three patients developed acute GvHD, two had grade I of the skin, one had aGvHD on day +131 (post-HSCT; +89 post-HSV-Tk DLI) grade II, which was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. Functionality of HSVTk gene expressing T-cells was shown by loss of bcr-abl gene expression as well as by control of cytomegalovirus-reactivation. To date, 6patients have relapsed and died, 2 after a second HSCT without T-cell depletion or administration of unmodified T-cells. Eleven patients (7 post-HSV-Tk DLI) are alive and well to date.

Original languageEnglish
Article number76
JournalFrontiers in Pharmacology
Volume6
Issue numberMAR
DOIs
Publication statusPublished - 2015

Fingerprint

Stem Cell Transplantation
Tissue Donors
T-Lymphocytes
Leukocyte Transfusion
abl Genes
Chimerism
Ganciclovir
Graft vs Host Disease
Hematologic Neoplasms
Retroviridae
Cytomegalovirus
Genes
Stem Cells
Transplantation
Clinical Trials
Safety
Gene Expression
Recurrence
Control Groups
Skin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Weissinger, E. M., Borchers, S., Silvani, A., Provasi, E., Radrizzani, M., Beckmann, I. K., ... Stadler, M. (2015). Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells. Frontiers in Pharmacology, 6(MAR), [76]. https://doi.org/10.3389/fphar.2015.00076

Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells. / Weissinger, Eva Maria; Borchers, Sylvia; Silvani, Anna; Provasi, Elena; Radrizzani, Marina; Beckmann, Irene Katarina; Benati, Claudia; Schmidtke, Joerg; Kuehnau, Wolfgang; Schweier, Patrick; Luther, Susanne; Fernandez-Munoz, Ivonne; Beutel, Gernot; Ciceri, Fabio; Bonini, Chiara; Ganser, Arnold; Hertenstein, Bernd; Stadler, Michael.

In: Frontiers in Pharmacology, Vol. 6, No. MAR, 76, 2015.

Research output: Contribution to journalArticle

Weissinger, EM, Borchers, S, Silvani, A, Provasi, E, Radrizzani, M, Beckmann, IK, Benati, C, Schmidtke, J, Kuehnau, W, Schweier, P, Luther, S, Fernandez-Munoz, I, Beutel, G, Ciceri, F, Bonini, C, Ganser, A, Hertenstein, B & Stadler, M 2015, 'Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells', Frontiers in Pharmacology, vol. 6, no. MAR, 76. https://doi.org/10.3389/fphar.2015.00076
Weissinger, Eva Maria ; Borchers, Sylvia ; Silvani, Anna ; Provasi, Elena ; Radrizzani, Marina ; Beckmann, Irene Katarina ; Benati, Claudia ; Schmidtke, Joerg ; Kuehnau, Wolfgang ; Schweier, Patrick ; Luther, Susanne ; Fernandez-Munoz, Ivonne ; Beutel, Gernot ; Ciceri, Fabio ; Bonini, Chiara ; Ganser, Arnold ; Hertenstein, Bernd ; Stadler, Michael. / Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells. In: Frontiers in Pharmacology. 2015 ; Vol. 6, No. MAR.
@article{e08a46ef62fc40c4ad57f5774efe61a2,
title = "Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells",
abstract = "Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for hematologic malignancies, but is hampered by severe complications, such as acute or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selcetion of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. Thus, we studied the efficacy, safety and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte transfusion (DLI). The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-Tk and the truncated LNGFR for selection of transduced cells. Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors).Nine patients were included in the first trial (MHH; 2002 until 2007) 2 were included in TK007 (2005-2009) and 6 serve as a control group for outcome after haploidentical transplantation without HSV-TKtransduced DLI. Three patients developed acute GvHD, two had grade I of the skin, one had aGvHD on day +131 (post-HSCT; +89 post-HSV-Tk DLI) grade II, which was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. Functionality of HSVTk gene expressing T-cells was shown by loss of bcr-abl gene expression as well as by control of cytomegalovirus-reactivation. To date, 6patients have relapsed and died, 2 after a second HSCT without T-cell depletion or administration of unmodified T-cells. Eleven patients (7 post-HSV-Tk DLI) are alive and well to date.",
author = "Weissinger, {Eva Maria} and Sylvia Borchers and Anna Silvani and Elena Provasi and Marina Radrizzani and Beckmann, {Irene Katarina} and Claudia Benati and Joerg Schmidtke and Wolfgang Kuehnau and Patrick Schweier and Susanne Luther and Ivonne Fernandez-Munoz and Gernot Beutel and Fabio Ciceri and Chiara Bonini and Arnold Ganser and Bernd Hertenstein and Michael Stadler",
year = "2015",
doi = "10.3389/fphar.2015.00076",
language = "English",
volume = "6",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "MAR",

}

TY - JOUR

T1 - Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-Tk transduced T-cells

AU - Weissinger, Eva Maria

AU - Borchers, Sylvia

AU - Silvani, Anna

AU - Provasi, Elena

AU - Radrizzani, Marina

AU - Beckmann, Irene Katarina

AU - Benati, Claudia

AU - Schmidtke, Joerg

AU - Kuehnau, Wolfgang

AU - Schweier, Patrick

AU - Luther, Susanne

AU - Fernandez-Munoz, Ivonne

AU - Beutel, Gernot

AU - Ciceri, Fabio

AU - Bonini, Chiara

AU - Ganser, Arnold

AU - Hertenstein, Bernd

AU - Stadler, Michael

PY - 2015

Y1 - 2015

N2 - Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for hematologic malignancies, but is hampered by severe complications, such as acute or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selcetion of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. Thus, we studied the efficacy, safety and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte transfusion (DLI). The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-Tk and the truncated LNGFR for selection of transduced cells. Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors).Nine patients were included in the first trial (MHH; 2002 until 2007) 2 were included in TK007 (2005-2009) and 6 serve as a control group for outcome after haploidentical transplantation without HSV-TKtransduced DLI. Three patients developed acute GvHD, two had grade I of the skin, one had aGvHD on day +131 (post-HSCT; +89 post-HSV-Tk DLI) grade II, which was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. Functionality of HSVTk gene expressing T-cells was shown by loss of bcr-abl gene expression as well as by control of cytomegalovirus-reactivation. To date, 6patients have relapsed and died, 2 after a second HSCT without T-cell depletion or administration of unmodified T-cells. Eleven patients (7 post-HSV-Tk DLI) are alive and well to date.

AB - Allogeneic stem cell transplantation (allo-HSCT) is one of the curative treatments for hematologic malignancies, but is hampered by severe complications, such as acute or chronic graft-versus-host-disease (aGvHD; cGvHD) and infections. CD34-selcetion of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. Thus, we studied the efficacy, safety and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte transfusion (DLI). The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-Tk and the truncated LNGFR for selection of transduced cells. Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors).Nine patients were included in the first trial (MHH; 2002 until 2007) 2 were included in TK007 (2005-2009) and 6 serve as a control group for outcome after haploidentical transplantation without HSV-TKtransduced DLI. Three patients developed acute GvHD, two had grade I of the skin, one had aGvHD on day +131 (post-HSCT; +89 post-HSV-Tk DLI) grade II, which was successfully controlled by ganciclovir (GCV). Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. Functionality of HSVTk gene expressing T-cells was shown by loss of bcr-abl gene expression as well as by control of cytomegalovirus-reactivation. To date, 6patients have relapsed and died, 2 after a second HSCT without T-cell depletion or administration of unmodified T-cells. Eleven patients (7 post-HSV-Tk DLI) are alive and well to date.

UR - http://www.scopus.com/inward/record.url?scp=84926616799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926616799&partnerID=8YFLogxK

U2 - 10.3389/fphar.2015.00076

DO - 10.3389/fphar.2015.00076

M3 - Article

VL - 6

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 76

ER -